Table 5.
Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)
| Study | Nitroxoline | Control | Indication | Patients (n) | Duration | End of therapy visit | Test of cure visit |
|---|---|---|---|---|---|---|---|
| NWNF 10° | Nitroxoline (NTX) | Cotrimoxazole (CTX) | Acute uncompl. cystitis | 130 total | 5 days | day 6 | day 12–14 |
| 3×250 mg | 2×960 mg | 67 NTX, 63 CTX | |||||
| NWNF 11 | Nitroxoline (NTX) | Cotrimoxazole (CTX) | Acute uncompl. cystitis | 115 total | 5 days | day 6 | day 12–14 |
| 3×250 mg | 2×960 mg | 56 NTX | |||||
| 59 CTX | |||||||
| NWNF 13 | Nitroxoline (NTX) | Norfloxacin (NFX) | Acute uncompl. cystitis | 105 total | 5 days | day 6 | day 12–14 |
| 3×250 mg | 2×400 mg | 51 NTX | |||||
| 54 NFX | |||||||
| NWNF 15 | Nitroxoline (NTX) | Cotrimoxazole (CTX) | Acute episode of uncompl. recurrent cystitis | 116 total | 10 days | day 11–13* | day 21–23 |
| 3×250 mg | 2×960 mg | 60 NTX | |||||
| 56 CTX |
°inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).
*additional visit during therapy: day 6–8.